EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.

导出原文传递

翻译打印收藏纠错

第一作者： Yuri,Sheikine

第一单位： Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

作者： Yuri,Sheikine ^[1] ; Deepa,Rangachari ^[2] ; Danielle C,McDonald ^[2] ; Mark S,Huberman ^[2] ; Erik S,Folch ^[3] ; Paul A,VanderLaan ^[4] ; Daniel B,Costa ^[5]

作者单位： Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. ^[1] Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA. ^[2] Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA. ^[3] Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA. ^[4] Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA. Electronic address: dbcosta@bidmc.harvard.edu. ^[5]

关键词 Adenocarcinoma Afatinib Erlotinib Exon 19 Gefitinib L858R Osimertinib T790M TKI

主题词抗肿瘤药(Antineoplastic Agents);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);人类(Humans);肺肿瘤(Lung Neoplasms);分子靶向治疗(Molecular Targeted Therapy);突变(Mutation);试验预期值(Predictive Value of Tests)

DOI 10.1016/j.cllc.2016.05.016

PMID 27381270

发布时间 2022-03-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交